Telix Pharmaceuticals (NASDAQ:TLX) Receives Buy Rating from HC Wainwright

Posted by Brenda Bartman on Sep 25th, 2026

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 74.67% from the company’s current price.

Several other research firms have also recently weighed in on TLX. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Finally, Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Buy” and an average price target of $20.50.

Get Our Latest Report on TLX

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock traded up $0.14 during trading hours on Friday, hitting $11.45. The company had a trading volume of 397,936 shares, compared to its average volume of 221,906. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11. The firm has a 50-day moving average of $11.33 and a 200 day moving average of $10.47.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XY Capital Ltd grew its position in shares of Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $1,731,000. Bank of America Corp DE grew its position in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Finally, Private Advisor Group LLC grew its position in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares in the last quarter.

About Telix Pharmaceuticals

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.